Skip to Content

January 2020 — Cellular Therapy

Chimeric antigen receptor T cells (CAR T cells) represent an exciting new area of cellular therapy. Manufacturing autologous CAR T cells involves virally transducing a patient’s T cells to express a receptor to heighten recognition of tumor-specific antigens. From a regulatory standpoint, CAR T cells are subject to regulation both as a drug and as a biological product. This presents ongoing challenges for cellular therapy programs and laboratories that seek to develop in-house manufacturing of next-generation CAR T cell products.

Image credit: National Cancer Institute

Your Score:  

Your Ranking:  

Photo of Ashley A. Krull, Ph.D.   Ashley Krull, Ph.D.
Fellow, Cellular Therapy
Mayo Clinic
@AshleyAKrull
Photo of Allan B. Dietz, Ph.D. Allan Dietz, Ph.D.
Consultant, Transfusion Medicine
Mayo Clinic
Associate Professor of Laboratory Medicine and Pathology
Instructor in Biochemistry and Molecular Biology
Mayo Clinic College of Medicine and Science
MCL Education

MCL Education

This post was developed by our Education and Technical Publications Team.